Aletta Kraneveld

Aletta Kraneveld

After obtaining her MSc in Pharmacy, Aletta Kraneveld worked at Glaxo Group Research (Ware, UK, 1990-1991). She obtained her PhD at the Utrecht University (1994) after which she continued her research at Harvard Medical School (Boston MA, USA, 1994). Being recognized by the Utrecht University as talented female researcher (UU award) Kraneveld was appointed as assistant professor in 1999 and in 2002 as associate professor at Utrecht University. 2016 Kraneveld was promoted to a joint appointment as Full Professor Interdisciplinary Translational Pharmacology at the faculties of Science and Veterinary Medicine. She has published 88 papers and presented over 35 invited lectures. Under her guidance 16 PhD-students successfully obtained their degree. Kraneveld is involved in the citizen initiative Immunowell (see www.immunowell.com) that focuses on defining a nation-wide research program on ‘Immune Fitness’ in a public-private setting with strong patient participation. Besides science, Kraneveld is active in policy and management. Since 2015 she is the chair of the Diversity Committee of the faculty of Science. Kraneveld is or has been an active member of several boards of the (inter)national scientific organizations (Dutch Society of Pharmacology, EPHAR, IUPHAR, Netherlands Federation of Innovative Drug research) as well as in Topsector Life Sciences & Health roadmap-teams and in the International review committee LSH Impulse.

Research

Her current research interests involve targeting the interaction between innate and adaptive immunity as well as host-microbiome interactions in chronic (inflammatory) diseases with pharmaceutical and nutritional interventions. As principle investigator Kraneveld is focusing her research to in depth study the role of the gut-immune-brain-axis in to further enhance knowledge of the interaction of the microbiome, immune and nervous system in chronic inflammatory conditions in the gut, airways and CNS. Kraneveld has set up a new research group within UU. The program is the start of a (inter)national neuro-immune platform where academia and industry meet for research on the gut-immune-brain axis as target for medicine and medical food concepts. The intestinal tract is our largest surface exposed to the environment inhabited with trillions of microbes. 70 % of our white blood cells once in their life pass the intestinal tract and are programmed also by the microbes. In addition, the intestinal tract is innervated by 100 million of neurons forming the enteric nervous system that can communicate bidirectionally with the brain, but is also involved in local (neuro)immunomodulatory processes. Kraneveld and colleagues have gained more insight, with state-of-the-art in vivo models as well as in cell systems, in the importance of the intestinal microbiome, its ligands/metabolites and receptors as well as the epithelium in the tuning of the immune system with consequences for local and remote organ functions such as lung and brain.

Selected publications

  1. Morgan, ME, et al, Kraneveld, AD (2014) TLR6 stimulation leads to an increased Th17 response in intestinal lymphoid tissue and worsens murine experimental colitis. Mucosal Immunol 7(5):1266-77
  2. Koelink, PJ, et al, Kraneveld, AD (2014) Collagen degradation and neutrophilic infiltration: a vicious circle in inflammatory bowel disease. Gut 63(4):578
  3. de Theije, CGM, et al, Kraneveld AD (2014) Intestinal inflammation in a murine model of autism spectrum disorders. Brain Behav Immun. 37:240 back-to-back with de Theije, CGM, et al (2014) Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun. 37:197

More information can be found on her staff page